Cholesterol mg/dL · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum fasting triglyceride (TG, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
HDL‐cholesterol · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Serum low‐density lipoprotein (LDL, mmol/L) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
CHD events · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease events compared with lower PUFA (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in stroke compared with lower PUFA (low certainty).
1 finding from 1 review
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Cardiovascular events · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular events compared with lower PUFA (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Atrial fibrillation and arrhythmias · people with or without existing cardiovascular disease, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes atrial fibrillation and arrhythmias compared with lower PUFA (very low certainty).
1 finding from 1 review
Weight (kg) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
ADHD symptoms – improvement – medium term · Children and adolescents with ADHD
Summary of findings table ‐ PUFA may leads to higher ADHD symptoms – improvement – medium term compared with placebo (low certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – inattention, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
Side effects – overall · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in side effects – overall compared with placebo (moderate certainty).
1 finding from 1 review
Loss to · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in loss to compared with placebo (moderate certainty).
1 finding from 1 review
Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in any adverse event (combined: diarrhoea, urinary tract infection,… compared with placebo (moderate certainty).
1 finding from 1 review
ADL outcome · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review